Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A

Lancet (London, England)29 Sept 2026

PMID42810372DOI10.1016/s0140-6736(26)01861-1PepBankPUB-42810372

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. 21 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, once-weekly retatrutide 12 mg reduced bodyweight at week 80 more than placebo.
In plain wordsIn adults with obesity and type 2 diabetes, retatrutide 12 mg led to more weight loss than placebo at week 80.
Peptide
Retatrutide
Outcome
DecreasePercent change in bodyweight at week 80
Study
n = 576
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
12 mg · subcutaneous · 80 weeksAs given in this study (human).
Measurements
Bodyweight change at week 80
−18.8%
retatrutide 12 mg
Bodyweight change at week 80
−5.1%
placebo
Treatment difference vs placebo
−13.8%
retatrutide 12 mg
Source sentences
Summary
For the treatment regimen estimand, the mean percentage change from baseline in bodyweight at week 80 was -11·9% (SE 0·6) with retatrutide 4 mg, -16·8% (0·7) with retatrutide 9 mg, -18·8% (0·7) with retatrutide 12 mg, and -5·1% (0·7) with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
-13·8% (-15·8 to -11·8) with retatrutide 12 mg (p<0·0001 for all).
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037203
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, once-weekly retatrutide 9 mg reduced bodyweight at week 80 more than placebo.
In plain wordsIn adults with obesity and type 2 diabetes, retatrutide 9 mg led to more weight loss than placebo at week 80.
Peptide
Retatrutide
Outcome
DecreasePercent change in bodyweight at week 80
Study
n = 573
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
9 mg · subcutaneous · 80 weeksAs given in this study (human).
Measurements
Bodyweight change at week 80
−16.8%
retatrutide 9 mg
Bodyweight change at week 80
−5.1%
placebo
Treatment difference vs placebo
−11.8%
retatrutide 9 mg
Source sentences
Summary
For the treatment regimen estimand, the mean percentage change from baseline in bodyweight at week 80 was -11·9% (SE 0·6) with retatrutide 4 mg, -16·8% (0·7) with retatrutide 9 mg, -18·8% (0·7) with retatrutide 12 mg, and -5·1% (0·7) with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
-11·8% (-13·7 to -9·8) with retatrutide 9 mg
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037202
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, once-weekly retatrutide 4 mg reduced bodyweight at week 80 more than placebo.
In plain wordsIn adults with obesity and type 2 diabetes, retatrutide 4 mg led to more weight loss than placebo at week 80.
Peptide
Retatrutide
Outcome
DecreasePercent change in bodyweight at week 80
Study
n = 581
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg · subcutaneous · 80 weeksAs given in this study (human).
Measurements
Bodyweight change at week 80
−11.9%
retatrutide 4 mg
Bodyweight change at week 80
−5.1%
placebo
Treatment difference vs placebo
−6.9%
retatrutide 4 mg
Source sentences
Summary
For the treatment regimen estimand, the mean percentage change from baseline in bodyweight at week 80 was -11·9% (SE 0·6) with retatrutide 4 mg, -16·8% (0·7) with retatrutide 9 mg, -18·8% (0·7) with retatrutide 12 mg, and -5·1% (0·7) with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
-6·9% (95% CI -8·7 to -5·1) with retatrutide 4 mg
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037201
04HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, permanent discontinuation due to adverse events or death with retatrutide 4 mg was not more frequent than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, stopping treatment for side effects or death was not more common with retatrutide 4 mg than placebo.
Peptide
Retatrutide
Outcome
No significant changePermanent discontinuation due to adverse events or death
Study
n = 581
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
4 mg · subcutaneousAs given in this study (human).
Measurements
Permanent discontinuation
4%
retatrutide 4 mg
Permanent discontinuation
5%
placebo
Source sentences
Summary
Permanent treatment discontinuation due to adverse events or death was more frequent in participants treated with retatrutide 9 mg (33 [12%]) and 12 mg (22 [8%]) compared with retatrutide 4 mg (11 [4%]) and placebo (14 [5%]).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037216
05HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, two participants died in the retatrutide 4 mg group; the investigator judged all deaths unrelated to the study intervention.
In plain wordsIn adults with obesity and type 2 diabetes, two people died in the retatrutide 4 mg group; the investigator judged the deaths unrelated to treatment.
Peptide
Retatrutide
Outcome
Direction not reportedDeaths
Study
n = 581
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
4 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Two participants died in the retatrutide 4 mg group, three in the 9 mg group, one in the 12 mg group, and one in the placebo group; all deaths were deemed to be unrelated to the study intervention by the investigator.
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037219
06HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, diarrhoea was more common with retatrutide 4 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, diarrhoea happened more often with retatrutide 4 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseDiarrhoea
Study
n = 579
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg · subcutaneousAs given in this study (human).
Measurements
Participants with diarrhoea
27%
retatrutide 4 mg
Participants with diarrhoea
13%
placebo
Source sentences
Summary
diarrhoea occurred in 80 [27%] of 292 participants in the 4 mg group, 95 [34%] of 284 in the 9 mg group, and 96 [34%] of 286 in the 12 mg group vs 38 [13%] of 287 in the placebo group
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037204
07HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, nausea was more common with retatrutide 4 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, nausea happened more often with retatrutide 4 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseNausea
Study
n = 579
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg · subcutaneousAs given in this study (human).
Measurements
Participants with nausea
14%
retatrutide 4 mg
Participants with nausea
8%
placebo
Source sentences
Summary
nausea occurred in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037207
08HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, hypotension was more frequent with retatrutide 4 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, low blood pressure happened more often with retatrutide 4 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseHypotension
Study
n = 579
Comparator
Placebo
Outcome group
Adverse events · Cardiovascular
Studied dose
4 mg · subcutaneousAs given in this study (human).
Measurements
Participants with hypotension
1%
retatrutide 4 mg
Source sentences
Summary
four [1%] in the 4 mg group, 14 [5%] in the 9 mg group, and 18 (6%) in the 12 mg group vs one [<1%] in the placebo group with hypotension
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037210
09HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, dysesthesia was more frequent with retatrutide 4 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, abnormal skin sensations happened more often with retatrutide 4 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseDysesthesia
Study
n = 579
Comparator
Placebo
Outcome group
Adverse events · Nervous system and cognition
Studied dose
4 mg · subcutaneousAs given in this study (human).
Measurements
Participants with dysesthesia
4%
retatrutide 4 mg
Participants with dysesthesia
1%
placebo
Source sentences
Summary
13 [4%], 16 [6%], and 21 [7%] vs two [1%] in the placebo group with dysesthesia
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037213
10HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, permanent discontinuation due to adverse events or death was more frequent with retatrutide 12 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, stopping treatment for side effects or death was more common with retatrutide 12 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreasePermanent discontinuation due to adverse events or death
Study
n = 576
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
12 mg · subcutaneousAs given in this study (human).
Measurements
Permanent discontinuation
8%
retatrutide 12 mg
Permanent discontinuation
5%
placebo
Source sentences
Summary
Permanent treatment discontinuation due to adverse events or death was more frequent in participants treated with retatrutide 9 mg (33 [12%]) and 12 mg (22 [8%]) compared with retatrutide 4 mg (11 [4%]) and placebo (14 [5%]).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037218
11HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, one participant died in the retatrutide 12 mg group; the investigator judged all deaths unrelated to the study intervention.
In plain wordsIn adults with obesity and type 2 diabetes, one person died in the retatrutide 12 mg group; the investigator judged the deaths unrelated to treatment.
Peptide
Retatrutide
Outcome
Direction not reportedDeaths
Study
n = 576
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
12 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Two participants died in the retatrutide 4 mg group, three in the 9 mg group, one in the 12 mg group, and one in the placebo group; all deaths were deemed to be unrelated to the study intervention by the investigator.
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037221
12HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, diarrhoea was more common with retatrutide 12 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, diarrhoea happened more often with retatrutide 12 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseDiarrhoea
Study
n = 573
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
12 mg · subcutaneousAs given in this study (human).
Measurements
Participants with diarrhoea
34%
retatrutide 12 mg
Participants with diarrhoea
13%
placebo
Source sentences
Summary
diarrhoea occurred in 80 [27%] of 292 participants in the 4 mg group, 95 [34%] of 284 in the 9 mg group, and 96 [34%] of 286 in the 12 mg group vs 38 [13%] of 287 in the placebo group
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037206
13HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, nausea was more common with retatrutide 12 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, nausea happened more often with retatrutide 12 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseNausea
Study
n = 573
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
12 mg · subcutaneousAs given in this study (human).
Measurements
Participants with nausea
28%
retatrutide 12 mg
Participants with nausea
8%
placebo
Source sentences
Summary
nausea occurred in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037209
14HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, hypotension was more frequent with retatrutide 12 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, low blood pressure happened more often with retatrutide 12 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseHypotension
Study
n = 573
Comparator
Placebo
Outcome group
Adverse events · Cardiovascular
Studied dose
12 mg · subcutaneousAs given in this study (human).
Measurements
Participants with hypotension
6%
retatrutide 12 mg
Source sentences
Summary
four [1%] in the 4 mg group, 14 [5%] in the 9 mg group, and 18 (6%) in the 12 mg group vs one [<1%] in the placebo group with hypotension
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037212
15HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, dysesthesia was more frequent with retatrutide 12 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, abnormal skin sensations happened more often with retatrutide 12 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseDysesthesia
Study
n = 573
Comparator
Placebo
Outcome group
Adverse events · Nervous system and cognition
Studied dose
12 mg · subcutaneousAs given in this study (human).
Measurements
Participants with dysesthesia
7%
retatrutide 12 mg
Participants with dysesthesia
1%
placebo
Source sentences
Summary
13 [4%], 16 [6%], and 21 [7%] vs two [1%] in the placebo group with dysesthesia
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037215
16HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, permanent discontinuation due to adverse events or death was more frequent with retatrutide 9 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, stopping treatment for side effects or death was more common with retatrutide 9 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreasePermanent discontinuation due to adverse events or death
Study
n = 573
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
9 mg · subcutaneousAs given in this study (human).
Measurements
Permanent discontinuation
12%
retatrutide 9 mg
Permanent discontinuation
5%
placebo
Source sentences
Summary
Permanent treatment discontinuation due to adverse events or death was more frequent in participants treated with retatrutide 9 mg (33 [12%]) and 12 mg (22 [8%]) compared with retatrutide 4 mg (11 [4%]) and placebo (14 [5%]).
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037217
17HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, three participants died in the retatrutide 9 mg group; the investigator judged all deaths unrelated to the study intervention.
In plain wordsIn adults with obesity and type 2 diabetes, three people died in the retatrutide 9 mg group; the investigator judged the deaths unrelated to treatment.
Peptide
Retatrutide
Outcome
Direction not reportedDeaths
Study
n = 573
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
9 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Two participants died in the retatrutide 4 mg group, three in the 9 mg group, one in the 12 mg group, and one in the placebo group; all deaths were deemed to be unrelated to the study intervention by the investigator.
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037220
18HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, diarrhoea was more common with retatrutide 9 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, diarrhoea happened more often with retatrutide 9 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseDiarrhoea
Study
n = 571
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · subcutaneousAs given in this study (human).
Measurements
Participants with diarrhoea
34%
retatrutide 9 mg
Participants with diarrhoea
13%
placebo
Source sentences
Summary
diarrhoea occurred in 80 [27%] of 292 participants in the 4 mg group, 95 [34%] of 284 in the 9 mg group, and 96 [34%] of 286 in the 12 mg group vs 38 [13%] of 287 in the placebo group
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037205
19HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, nausea was more common with retatrutide 9 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, nausea happened more often with retatrutide 9 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseNausea
Study
n = 571
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 mg · subcutaneousAs given in this study (human).
Measurements
Participants with nausea
21%
retatrutide 9 mg
Participants with nausea
8%
placebo
Source sentences
Summary
nausea occurred in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037208
20HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, hypotension was more frequent with retatrutide 9 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, low blood pressure happened more often with retatrutide 9 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseHypotension
Study
n = 571
Comparator
Placebo
Outcome group
Adverse events · Cardiovascular
Studied dose
9 mg · subcutaneousAs given in this study (human).
Measurements
Participants with hypotension
5%
retatrutide 9 mg
Source sentences
Summary
four [1%] in the 4 mg group, 14 [5%] in the 9 mg group, and 18 (6%) in the 12 mg group vs one [<1%] in the placebo group with hypotension
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037211
21HumanRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, dysesthesia was more frequent with retatrutide 9 mg than with placebo.
In plain wordsIn adults with obesity and type 2 diabetes, abnormal skin sensations happened more often with retatrutide 9 mg than with placebo.
Peptide
Retatrutide
Outcome
IncreaseDysesthesia
Study
n = 571
Comparator
Placebo
Outcome group
Adverse events · Nervous system and cognition
Studied dose
9 mg · subcutaneousAs given in this study (human).
Measurements
Participants with dysesthesia
6%
retatrutide 9 mg
Participants with dysesthesia
1%
placebo
Source sentences
Summary
13 [4%], 16 [6%], and 21 [7%] vs two [1%] in the placebo group with dysesthesia
2 context sentences(design, population, supporting numbers)
Summary · context
We enrolled adults (aged ≥18 years) with a BMI of 27 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] 6·5-10·5%) on stable treatment for type 2 diabetes for at least 90 days before screening (diet or exercise alone, or up to three oral glucose-lowering medicati…
Summary · context
Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to receive once-weekly subcutaneous injections (self-administered) of placebo or retatrutide 4 mg, 9 mg, or 12 mg.
Report a problemFND-4281037214

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT05929079

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Eli Lilly and Companyn = 1,15211 Jul 2023 to 16 Jun 2026

Type 2 Diabetes · Obesity · Overweight · Obstructive Sleep Apnea

Trial page ClinicalTrials.govUpdated 30 Jul 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

PepBank is a research reference. Talk to a doctor before you use any peptide.